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Mechanisms of endogenous pain control are signiﬁcant. Increasing studies have clearly
produced evidence for the clinical usefulness of opioids in peripheral analgesia.The immune
system uses mechanisms of cell migration not only to ﬁght pathogens but also to control
pain and inﬂammation within injured tissue. It has been demonstrated that peripheral
inﬂammatory pain can be effectively controlled by an interaction of immune cell-derived
opioid peptides with opioid receptors on peripheral sensory nerve terminals. Experimental
and clinical studies have clearly shown that activation of peripheral opioid receptors with
exogenous opioid agonists and endogenous opioid peptides are able to produce signiﬁcant
analgesic and anti-inﬂammatory effects, without central opioid mediated side effects (e.g.,
respiratory depression, sedation, tolerance, dependence).This article will focus on the role
of opioids in peripheral inﬂammatory conditions and the clinical implications of targeting
peripheral opioid receptors.
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INTRODUCTION
Inﬂammation is the series of highly coordinated events that is the
response of vascular tissues to detrimental stimuli which results
in heat, swelling, redness, and pain (Machelska et al., 2003). It
is a vital protective response that functions to provide a rapid
response to injuries to stimulate repair and prevent further distur-
bance to the affected tissue (Stein et al., 2003). Acute peripheral
inﬂammatory pain is associated with immediate immune cell
inﬁltration following tissue damage. Several disorders are corre-
lated with peripheral inﬂammatory pain, such as arthritis and
soft tissue injuries. Hyperalgesia, which is a lowered threshold
to pain, is also associated with inﬂammatory pain. After tissue
damage, residentmacrophages generate an inﬂammatory response
via release of mediators. These cause local inﬂammatory changes
as well as attract more leukocytes to the site of inﬂammation
which amplify these changes. Inﬂammatory mediators that are
released and tissue acidiﬁcation activate nociceptive primary affer-
ent neurons as well as lower their signaling threshold in order to
stimulate the sensation of pain and cause hyperalgesia (Hua and
Cabot, 2010).
ROLE OF ENDOGENOUS OPIOID SYSTEMS IN
INFLAMMATION
An excess of pain or long-lasting pain (not necessarily“chronic”) is
counterproductive and so the body utilizes endogenous analgesic
compounds to alleviate this sensation (Stein, 2013). Endogenous
pain controlmechanisms arenot limited to the central nervous sys-
tem (CNS). Although central mechanisms play a prominent role,
evidence in the literature also suggests a signiﬁcant involvement of
peripheral mechanisms in counteracting pain. In fact, peripheral
analgesic mechanisms have been demonstrated both in animals
and humans, especially under inﬂammatory conditions. Most of
these involve the release of opioid peptides, endocannabinoids,
somatostatin, or anti-inﬂammatory cytokines (Przewlocki et al.,
1992; Luster et al., 2005; Hua and Cabot, 2010). Opioid peptides
and their roles in anti-nociception have been extensively exam-
ined and their clinical relevance has been demonstrated in both
human and animal studies (Busch-Dienstfertig and Stein, 2010;
Stein, 2013).
Opioid-mediated analgesia is instigated in both the CNS and
periphery through the release of endogenous opioid peptides. Evi-
dence from the literature has shown that the central and peripheral
mechanisms of endogenous opioid analgesia are interconnected,
particularly in the early stages of inﬂammation (Binder et al., 2004;
Brack et al., 2004d; Labuz et al., 2007; Hua and Cabot, 2010). The
later stages have shown to have an increased role for peripheral
opioid antinociception (Labuz et al., 2006, 2007). In the periph-
ery, immune cells have been demonstrated to contain and release
the opioid peptide β-endorphin in inﬂamed tissues which then
acts upon opioid receptors present on primary afferent neurons
to block pain transmission and thus provide analgesia (Mousa
et al., 2000; Vetter et al., 2006). Labuz et al. (2006) demonstrated
that treatment of inﬂamed tissue with anti-β-endorphin antibody
attenuated endogenous antinociceptive effects in this tissue. This
local opioid-mediated effect is limited to the periphery and thus
does not have the adverse systemic effects of centrally mediated
opioid analgesia (Labuz et al., 2006).
OPIOID PEPTIDES AND RECEPTORS IN INFLAMMATION
There are three families of opioid peptides that have been exten-
sively studied: the endorphins, enkephalins and dynorphins,
each of which is derived from a distinct gene and the precur-
sors, pro-opiomelanocortin (POMC), pro-enkephalin (PENK)
and prodynorphin (Hua and Cabot, 2010; Busch-Dienstfertig and
Stein, 2010). Once released from immune cells opioid peptides act
uponopioid receptors that are locatedonprimary afferent neurons
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and have been shown to be co-localized with nociceptors (Joseph
and Levine, 2010; Wang et al., 2010; Stein, 2013). Opioid peptides
render nociceptors less sensitive to excitation and thus impede the
action of multiple excitatory mediators in one step. Each opioid
peptide does not bind exclusively to one unique opioid receptor
but instead exhibits afﬁnity for various opioid receptors including
μ-, ∂- and κ-opioid receptors. During states of inﬂammation the
numbers of opioid receptors in the periphery have been noted to
be increased. For example, Jeanjean et al. (1995) showed that a
single intraplantar injection of interleukin-1β (IL-1β) was able to
enhance the axonal transport of mu and kappa opioid receptors in
the injected paw for as long as 6 days following a single injection.
This increase in receptors is due to an increase in receptor synthe-
sis, not an increase in speed of axonal transport, and it is theorized
to occur through IL-1β stimulated retrograde axonal transport
of cytokines and nerve growth factor from the inﬂamed tissue
that alter neuronal gene expression in dorsal root ganglia neurons
(Jeanjean et al., 1995; Puehler et al., 2004; Busch-Dienstfertig and
Stein, 2010).
Enzymes within neurons such as phosphokinase C can phos-
phorylate opioid receptors, which leads to an increased afﬁnity for
arrestin molecules. Opioid-arrestin complexes have a decreased
sensitivity for extracellular opioid peptides and are likely to be
internalized via clathrin-dependent pathways (Law et al., 2000;
Busch-Dienstfertig and Stein, 2010). From here, the receptors can
either be recycled by reinsertion into the membrane, or they can
be degraded. Recycling of peripheral opioid receptors has been
shown to avoid the development of tolerance to opioids in the
periphery via prevention of desensitization (Koch et al., 2005).
Opioid peptides also work to prevent vesicular release from neu-
rons via inhibition of ion channels, which prevents the release
of excitatory neuropeptides such as noradrenaline and substance
P (Stein, 2013). As tolerance is a signiﬁcant problem associated
with systemic administration of opioids, the targeting of periph-
eral opioid receptors, which have innate mechanisms to prevent
desensitization, is clinically relevant (Joseph et al., 2010).
OPIOID-CONTAINING IMMUNE CELLS IN INFLAMMATION
Inﬂammation rapidly stimulates immune cell extravasation and
migration into tissues (Machelska et al., 2004; Rittner and Stein,
2005). Quantitative analysis has revealed that in early inﬂam-
mation granulocytes (esp. neutrophils) are the major opioid-
containing leukocyte, whereas at later stages of inﬂammation,
monocytes/macrophages and lymphocytes (esp. activated T- and
B-cells) predominate (Rittner et al., 2001; Brack et al., 2004a,b;
Machelska et al., 2004). This is consistent with their order of inﬁl-
tration to inﬂamed tissues (Luster et al., 2005). Inﬂammation has
been shown to increase the expression of opioid peptides within
these cells. In fact all opioid peptides as well as their mRNA
transcripts encoding their precursor proteins have been identi-
ﬁed within immune cell, with β-endorphin from POMC being
the most prominent (Cabot et al., 1997; Cabot, 2001; Mousa et al.,
2001). However, it has been suggested that only a ﬁnite number
of the total immune cell population actually produce opioid pep-
tides and home to lymph nodes (Stein et al., 2003; Rittner et al.,
2005). This is supported by the observation that β-endorphin and
POMCmRNAwere less abundant in circulating lymphocytes than
in those in lymph nodes (Cabot et al., 1997). Similarly, Przewlocki
et al. (1992) demonstrated the presence of immune cells contain-
ing the opioid peptide precursors, POMC and PENK, in inﬂamed
tissue and the absence of these mRNA in non-inﬂamed tissue.
Labuz et al. (2006) identiﬁed that the majority of immune cells
inﬁltrating inﬂamed tissue containedβ-endorphin. Thereforewith
the duration of inﬂammation, the number of inﬁltrating immune
cells aswell as total opioidpeptide content at the site of tissue injury
increases. These opioid peptides are translated andprocessed at the
site of inﬂammation within immune cells.
MIGRATION OF OPIOID-CONTAINING LEUKOCYTES TO
INFLAMED TISSUE
Peripheral tissue injury causes a migration of opioid peptide-
containing immune cells to the inﬂamed site. This migration
appears to be both centrally and locally regulated. Exogenously
stimulated systemic inhibition of pain has been shown to decrease
the recruitment of β-endorphin containing immune cells in
inﬂamed tissue (Schmitt et al., 2003; Heurich et al., 2007), thus
suggesting a role for central regulation. Local regulation has been
more extensively studied and involves a series of binding events
to endothelial cells. The trafﬁcking of opioid-containing immune
cells occurs in a site-directed manner since they express adhe-
sion molecules that govern their recruitment to damaged tissue
(Schmitt et al., 2003). The homing of leukocytes to inﬂamed tis-
sues involves a precise series of events which begin with circulating
leukocytes tethering to and rolling along the vascular endothe-
lial cell wall in a process mediated by P-, E-, and L-selectins
(Koning et al., 2002; Stein et al., 2003; Figure 1). Upregula-
tion of these cell adhesion molecules has been noted in many
models of inﬂammation (Schurmann et al., 1995; Krishna et al.,
1997; Navarro et al., 2002; Almulki et al., 2009; Svensson et al.,
2009). Leukocytes are then activated by chemokines released
from inﬂammatory cells and presented on the luminal surface
of the endothelium (Koning et al., 2002; Machelska et al., 2002;
Stein et al., 2003). This causes an increase in the avidity as
well as an up-regulation of leukocyte integrins, in particular
CD49d/CD29 and CD18, which mediate the ﬁrm adhesion of
leukocytes to endothelial cells by interacting with intercellular
adhesion molecule-1 (ICAM-1; Koning et al., 2002; Machelska
et al., 2002; Stein et al., 2003). Leukocytes then migrate through
the endothelium with the aid of platelet-endothelial cell adhesion
molecule-1 (PECAM-1) expressed on endothelial cells at intercel-
lular junctions. All these molecules are constitutively expressed
and are upregulated in inﬂammation, except L-selectin, which
is rapidly shed upon activation (Koning et al., 2002; Muro and
Muzykantov, 2005). The up-regulation of these necessary com-
ponents of leukocyte transmigration in inﬂammation results in
the increased inﬂux of immune cells. The preferential increase
in opioid-containing immune cells can be explained by the co-
expression of L-selectin, integrin-β and the chemokine receptor
CXCR2 on opioid-containing leukocytes (Mousa et al., 2000;
Brack et al., 2004a,b,c,d; Machelska et al., 2004). Pre-treatment of
rats with antibodies against these molecules have been shown to
signiﬁcantly decrease the number of opioid-containing immune
cells that accumulate in inﬂamed tissue (Machelska et al., 1998,
2002, 2004).
Frontiers in Pharmacology | Inﬂammation Pharmacology October 2013 | Volume 4 | Article 132 | 2
“fphar-04-00132” — 2013/10/22 — 22:12 — page 3 — #3
Iwaszkiewicz et al. Targeting peripheral opioid receptors
FIGURE 1 | Migration of opioid-containing immune cells and opioid
release within inflamed tissue. Adhesion molecules interact with their
respective ligands to facilitate endothelial transmigration of immune cells. In
response to stress or releasing agents (e.g., CRF, IL-1, CXCL8), the immune
cells secrete opioid peptides. Opioid peptides or exogenous opioids bind to
opioid receptors on primary afferent neurons, leading to analgesia. Direct
adhesion between opioid-containing immune cells and peripheral sensory
neurons (via ICAM-1 and/or NCAM) may be necessary to release opioid
peptides within the effective range of peripheral opioid receptors. The
immune cells, depleted of opioids, then migrate to regional lymph nodes. The
arrows denote an increased expression within inﬂamed tissue of cell
adhesion molecules, opioid receptors, endogenous opioid peptides, and
receptors for ligands that trigger opioid release on the surface of immune
cells (e.g., CXCR2, IL-1 receptors, CRF receptors). This all enhances the
analgesic and anti-inﬂammatory activity of the peripheral opioid pathway in
inﬂammatory conditions.
RELEASE OF OPIOID PEPTIDES FROM LEUKOCYTES
Opioid-containing immune cells release opioid peptides within
peripheral inﬂamed tissue before moving to the local lymph node
(Hua and Cabot, 2010). The release of opioids has been demon-
strated to be governed by various factors. The chemokine CXCL8
(also known as IL-8) in humans which acts upon CXCR2 has
likewise been demonstrated to increase release of opioid pep-
tides in vitro. CXCL8-mediated opioid release occurs via binding
of CXCL8 to its receptor on the leukocyte, which causes vesic-
ular release of opioid peptides in a calcium-dependant manner
(Rittner et al., 2006). This is the same process that is used by other
inﬂammatory factors such as corticotropin-releasing factor (CRF)
and IL-1β.
Schafer et al. (1997) demonstrated the ability of CRF to cause
opioid release in vitro from immune cells obtained from inﬂamed
tissue. Labuz et al. (2006) through the use of anti-β-endorphin
antibody in vivo showed that release of β-endorphin from immune
cells is mediated by CRF interacting with its respective receptor
on leukocytes. CRF and its respective receptors on the surface of
leukocytes are upregulated in inﬂammation (Schafer et al., 1997).
Schafer et al. (1997) further demonstrated that IL-1β inﬂuences
the release of β-endorphin from immune cells both in vitro and
in vivo when administered locally via receptor binding. IL-1β lev-
els increase during inﬂammation and enacts a positive feedback
loop in order to increase its own concentration, whilst also having
pro-inﬂammatory effects by upregulating the release of inﬂam-
matory factors (Schafer, 2003; Jimbo et al., 2005). Therefore as
inﬂammation progresses, the level of endogenous opioid release
also increases.
β-endorphin containing inﬂammatory cells situated in close
proximity to sympathetic nerve ﬁbres within inﬂamed tissue
have also been observed to possess increased numbers of α1-
and β2-adrenergic receptors. Destruction of these receptors was
demonstrated to abolish endogenous opioid analgesia, thus sug-
gesting that noradrenaline release by neuronal cells may also
stimulate the release of opioid peptides (Binder et al., 2004;
Machelska et al., 2004).
THE EFFECT OF INFLAMMATORY CONDITIONS ON OPIOID
EFFICACY
The rate of metabolic degradation of opioid peptides is increased
in inﬂamed tissues (Vetter et al., 2006; Schreiter et al., 2012).
Release of inﬂammatory factors such as hydrogen ions from
damaged cells, cytokines and chemokines from resident cells
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and peptidases from immune and neuronal cells create a hos-
tile environment that acts to quickly break down opioids (Vetter
et al., 2006; Schreiter et al., 2012). In order for opioid peptides
to reach their receptors on nociceptive primary afferent neu-
rons, interaction between neurons and immune cells may be
required.
Recent reports have described bidirectional communication
between immune and neuronal cells as well as physical contact
between these cells. Of note is the observation of peripheral nerves
and opioid-containing immune cells being closely associated
(Przewlocki et al., 1992; Hua et al., 2006; Hua and Cabot, 2010).
In vitro studies have demonstrated consistent alliance between
lymphocytes containing opioids and cultured DRG nerves (Hua
et al., 2006) whilst in vivo studies has observed this same phenom-
ena in peripheral inﬂamed tissues with primary afferent nerves
(Przewlocki et al., 1992). The mechanics of this association are
yet to be elucidated, but is likely to be either by a synaptic-like
connection being formed or paracrine opioid release. Adhesion
molecules come into play with both of these processes in order
to form intercellular interactions that are stable and cell speciﬁc
(Dustin and Colman, 2002; Yamagata et al., 2003). Inhibition
of ICAM-1 and neural cell adhesion molecules (NCAM) have
both been demonstrated to result in a decrease lymphocyte–
DRG neuronal cell interactions (Hua et al., 2006), which suggests
that these play an important role in immune and neuronal cell
adhesion. Whilst the exact mechanisms of these interactions
are not yet understood, they may play a necessary role in the
development of effective endogenous analgesia by ensuring deliv-
ery of opioids to peripheral sensory neurons before they are
degraded by the extracellular environment within inﬂamed tissues
(Figure 1).
ANTI-INFLAMMATORY EFFECT OF PERIPHERAL OPIOIDS
Endogenous opioids may enact anti-inﬂammatory effects as well
as analgesia through their actions on neuronal cells through pre-
vention of vesicular release of noradrenaline and substance P.
The function of noradrenaline in inﬂammation is contested, with
evidence being provided for both a positive and negative role.
Schlachetzki et al. (2010) observed enhanced expression of COX-2,
which is heavily implicated in inﬂammation, following treat-
ment with noradrenaline. However, data has also been presented
that correlates noradrenaline release in Alzheimer’s disease with
suppression of neuroinﬂammation (Heneka et al., 2010). Sub-
stance P conversely has a well-reviewed pro-inﬂammatory action
(O’Connor et al., 2004). Walker (2003) suggests that an opioid-
mediated reduction of tumour necrosis factor (TNF) production
and release also contributes to anti-inﬂammatory actions. TNF is
a known regulator of inﬂammation and its inhibition has been
shown to be an effective anti-inﬂammatory treatment (Esposito
and Cuzzocrea, 2009). As the process of blocking the release of
these neuropeptides is due to opioid receptor mediated hyperpo-
larisation of neuronal cells, exogenous opioids theoretically should
have the same anti-inﬂammatory effect.
An opioid receptor independent mechanism may also be
involved in opioid-mediated anti-inﬂammation. Gavalas et al.
(1994) showed that experimentally induced mouse paw oedema
was signiﬁcantly inhibited after the administration of opioids and
this effect was not reversed by naxolone. Conversely, Philippe
et al. (2003) noted that naxolone was able to reverse the mu-
opioid receptormediated reduction in inﬂammation in two in vivo
models of colitis. These results suggest that a variety of complex
regulatory activities may be performed by opioid agonists in vari-
ous tissues of the body that may be naloxone-sensitive or naloxone
insensitive and these pathways may directly or indirectly inhibit
the release of cytokines and mediators involved in inﬂammation
(Gavalas et al., 1994).
Fecho et al. (2007) demonstrated an anti-inﬂammatory action
of morphine through the reduction of swelling and accumulation
of neutrophils in carrageenan-induced peripheral inﬂammation.
This effect was not dose-dependent and was not reversed by
naloxone. The anti-inﬂammatory effect displayed by morphine
is likely due to modulation of the adherence of immune cells
to the endothelium by affecting the expression of cell adhesion
molecules, and consequently affecting leukocyte transmigra-
tion. In comparison, administration of liposomes loaded with
loperamide HCl and conjugated with antibody to intercellular
adhesion molecule-1 (anti-ICAM-1), exerted analgesic and anti-
inﬂammatory effects exclusively in peripheral painful inﬂamed
tissue when administered intravenously in the complete Freund’s
adjuvant (CFA) model of acute inﬂammatory pain (Hua and
Cabot, 2013). It was demonstrated previously that this adhesion
between opioid-containing lymphocytes and cultured sensory
neurons was opioid receptor dependent, with naloxone inhibiting
the reduced neuroimmune adhesion in the presence of beta-
endorphin (Hua et al., 2006). Opioids have been found to have
signiﬁcant anti-inﬂammatory effects in peripheral inﬂamed tis-
sues, thus they are of clinical signiﬁcance in relation to the
treatment of peripheral inﬂammatory pain.
CLINICAL IMPLICATIONS AND PERSPECTIVES
TOPICAL OPIOID DELIVERY
Topically applied opioids have already been employed as a way
of instigating peripheral nociception, however further studies are
required to ascertain the anti-inﬂammatory activity of topical opi-
oids. Case studies have reported the effectiveness of morphine
when combined with pre-made gels such as IntraSite® for use
in ulcers. van Ingen et al. (2010) recorded a case where topical
morphine gel was applied to a cutaneous ulcer that had previously
been treated unsuccessfullywith zinc oil and surgical debridement.
Within 3 days of the start of morphine gel treatment, the visual
analog scale (VAS; 0–100) for pain, as determined by the patient,
was halved from 80 to 40 (van Ingen et al., 2010). Welling (2007)
explored the use of topical morphine in burns patients as a way
of providing analgesia and avoiding systemic side effects, however
no signiﬁcant evidence of analgesia was seen when compared to
the control groups. This study had a low level of power with a
small number of participants, and damaged neuronal cells in burn
patients may also account for the lack of efﬁcacy in comparison
to studies on chronic inﬂammatory wounds. This may be due to
damaged nerve endings that result in impaired signal transduc-
tion or receptor expression. Loperamide has been reported upon
in relation to the treatment of thermal injury in animals. Topi-
cal delivery of loperamide was used by Nozaki-Taguchi and Yaksh
(1999) to successfully initiate antihyperalgesia in rats after thermal
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injury (Nozaki-Taguchi and Yaksh, 1999). In humans, loperamide
has been used in solution for analgesia in graft-versus-host related
oral pain (Nozaki-Taguchi et al., 2008). Nozaki-Taguchi et al.
(2008) studied four patients whowere suffering fromoral pain fol-
lowing blood stem cell transplantation. Utilizing the loperamide
mouthwash resulted in oral analgesia and reduction of hyperalge-
sia in these patients. Analgesia was not noted in any other parts
of the body, but some inhibition of gut motility was exhibited
(Nozaki-Taguchi et al., 2008).
PARENTERAL OPIOID DELIVERY
Peripheral mechanisms of opioid analgesia are well-established in
the literature and have gained recognition in the clinical setting in
conditions such as chronic rheumatoid arthritis and osteoarthri-
tis, bone pain, and postoperative pain after laparoscopic, urinary
bladder, and knee surgery (Busch-Dienstfertig and Stein, 2010). In
patients undergoing arthroscopic knee surgery, opioid-containing
immune cells are detectable in the inﬂamed synovium and the
blockade of intra-articular opioid receptors by naloxone results in
signiﬁcantly increased postoperative pain for up to 4 h (Stein et al.,
1993). More recently, peripheral opioid analgesia has also been
reported in experimental neuropathic pain (Labuz et al., 2009,
2010).
The most extensively studied clinical situation is the intra-
articular application of opioid agonists for pain control after
knee surgery (Stein and Lang, 2009; Busch-Dienstfertig and Stein,
2010), which is now established in routine clinical practice (Lang
et al., 2010). Intra-articular morphine was found to be as potent
as dexamethasone in reducing pain as well as synovial inﬂamma-
tion (Stein et al., 1999). However, a limitation of intra-articular
administration of opioids is that repeated injections carry a risk
of infection and cannot be easily applied to more than one joint.
Negative results from some reviews have been attributed to lack of
study sensitivity, lack of tissue inﬂammation, or the superimpo-
sition of general or local anesthetic effects (Stein and Machelska,
2011). Importantly, the use of peripherally acting opioid ago-
nists for the prolonged treatment of inﬂammatory pain has not
been shown to induce peripheral tolerance (Zollner et al., 2008;
Lang et al., 2010), which has important implications for the treat-
ment of pain associated with conditions such as chronic arthritis,
inﬂammatory neuropathy, postoperative pain and cancer. Unfor-
tunately the clinical studies to date were not designed to focus
on the anti-inﬂammatory potential of opioids, as this is a more
recent established ﬁnding of peripheral opioid therapy. There-
fore, future clinical studies should incorporate both quantitative
and qualitative anti-inﬂammatory measures into the research
design.
CONCLUSION
Increasing studies have clearly produced evidence for the clinical
usefulness of peripheral opioid analgesics, in particular adminis-
tration of opioids into local inﬂamed tissue. A major long-term
goal remains to develop peripherally selective opioid compounds,
suitable for oral and/or intravenous route of administration to
improve clinical pain relief. Peripherally targeted opioids may
be used in a co-treatment approach with other therapies (e.g.,
cytokine modulators or TNF-α antagonists) at low doses for con-
ditions such as rheumatoid arthritis. This may provide a much
sought after alternative for the management of chronic arthritic
and other inﬂammatory conditions whilst avoiding central opi-
oid mediated side effects and of typical side effects produced by
non-steroidal and steroidal anti-inﬂammatory drugs.
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